1544 related articles for article (PubMed ID: 31695329)
1. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview.
Bagchi S; Chhibber T; Lahooti B; Verma A; Borse V; Jayant RD
Drug Des Devel Ther; 2019; 13():3591-3605. PubMed ID: 31695329
[TBL] [Abstract][Full Text] [Related]
2. Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules.
Harilal S; Jose J; Parambi DGT; Kumar R; Unnikrishnan MK; Uddin MS; Mathew GE; Pratap R; Marathakam A; Mathew B
Brain Res Bull; 2020 Jul; 160():121-140. PubMed ID: 32315731
[TBL] [Abstract][Full Text] [Related]
3. Blood-Brain Barrier (BBB)-Crossing Strategies for Improved Treatment of CNS Disorders.
Zhang W
Handb Exp Pharmacol; 2024; 284():213-230. PubMed ID: 37528323
[TBL] [Abstract][Full Text] [Related]
4. Blood-brain barrier structure and function and the challenges for CNS drug delivery.
Abbott NJ
J Inherit Metab Dis; 2013 May; 36(3):437-49. PubMed ID: 23609350
[TBL] [Abstract][Full Text] [Related]
5. The barrier and interface mechanisms of the brain barrier, and brain drug delivery.
Zhang S; Gan L; Cao F; Wang H; Gong P; Ma C; Ren L; Lin Y; Lin X
Brain Res Bull; 2022 Nov; 190():69-83. PubMed ID: 36162603
[TBL] [Abstract][Full Text] [Related]
6. Mimicking brain tissue binding in an in vitro model of the blood-brain barrier illustrates differences between in vitro and in vivo methods for assessing the rate of brain penetration.
Heymans M; Sevin E; Gosselet F; Lundquist S; Culot M
Eur J Pharm Biopharm; 2018 Jun; 127():453-461. PubMed ID: 29602020
[TBL] [Abstract][Full Text] [Related]
7. A Human Immortalized Cell-Based Blood-Brain Barrier Triculture Model: Development and Characterization as a Promising Tool for Drug-Brain Permeability Studies.
Ito R; Umehara K; Suzuki S; Kitamura K; Nunoya KI; Yamaura Y; Imawaka H; Izumi S; Wakayama N; Komori T; Anzai N; Akita H; Furihata T
Mol Pharm; 2019 Nov; 16(11):4461-4471. PubMed ID: 31573814
[TBL] [Abstract][Full Text] [Related]
8. CNS drug delivery systems: novel approaches.
Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
[TBL] [Abstract][Full Text] [Related]
9. Recent progress and new challenges in modeling of human pluripotent stem cell-derived blood-brain barrier.
Yan L; Moriarty RA; Stroka KM
Theranostics; 2021; 11(20):10148-10170. PubMed ID: 34815809
[TBL] [Abstract][Full Text] [Related]
10. In vitro models of the blood-brain barrier.
Wilhelm I; Fazakas C; Krizbai IA
Acta Neurobiol Exp (Wars); 2011; 71(1):113-28. PubMed ID: 21499332
[TBL] [Abstract][Full Text] [Related]
11. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?
Sanchez-Covarrubias L; Slosky LM; Thompson BJ; Davis TP; Ronaldson PT
Curr Pharm Des; 2014; 20(10):1422-49. PubMed ID: 23789948
[TBL] [Abstract][Full Text] [Related]
12. Nano carriers for drug transport across the blood-brain barrier.
Li X; Tsibouklis J; Weng T; Zhang B; Yin G; Feng G; Cui Y; Savina IN; Mikhalovska LI; Sandeman SR; Howel CA; Mikhalovsky SV
J Drug Target; 2017 Jan; 25(1):17-28. PubMed ID: 27126681
[TBL] [Abstract][Full Text] [Related]
13. Drug penetration across the blood-brain barrier: an overview.
Mangas-Sanjuan V; González-Alvarez M; Gonzalez-Alvarez I; Bermejo M
Ther Deliv; 2010 Oct; 1(4):535-62. PubMed ID: 22833966
[TBL] [Abstract][Full Text] [Related]
14. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction.
Engelhardt B; Sorokin L
Semin Immunopathol; 2009 Nov; 31(4):497-511. PubMed ID: 19779720
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics.
Bergmann S; Lawler SE; Qu Y; Fadzen CM; Wolfe JM; Regan MS; Pentelute BL; Agar NYR; Cho CF
Nat Protoc; 2018 Dec; 13(12):2827-2843. PubMed ID: 30382243
[TBL] [Abstract][Full Text] [Related]
16. In silico prediction models for blood-brain barrier permeation.
Ecker GF; Noe CR
Curr Med Chem; 2004 Jun; 11(12):1617-28. PubMed ID: 15180567
[TBL] [Abstract][Full Text] [Related]
17. Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB.
Nagpal K; Singh SK; Mishra DN
Expert Opin Drug Deliv; 2013 Jul; 10(7):927-55. PubMed ID: 23330786
[TBL] [Abstract][Full Text] [Related]
18. Microfluidic blood-brain barrier model provides in vivo-like barrier properties for drug permeability screening.
Wang YI; Abaci HE; Shuler ML
Biotechnol Bioeng; 2017 Jan; 114(1):184-194. PubMed ID: 27399645
[TBL] [Abstract][Full Text] [Related]
19. Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances.
Goyal K; Koul V; Singh Y; Anand A
Cent Nerv Syst Agents Med Chem; 2014; 14(1):43-59. PubMed ID: 25360772
[TBL] [Abstract][Full Text] [Related]
20. Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents.
Cho CF; Wolfe JM; Fadzen CM; Calligaris D; Hornburg K; Chiocca EA; Agar NYR; Pentelute BL; Lawler SE
Nat Commun; 2017 Jun; 8():15623. PubMed ID: 28585535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
